News headlines about Novan (NASDAQ:NOVN) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novan earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.7758659490631 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Novan (NOVN) remained flat at $$3.31 during midday trading on Tuesday. The company’s stock had a trading volume of 1,704 shares, compared to its average volume of 95,368. The stock has a market cap of $87.06, a P/E ratio of -0.42 and a beta of 1.26. Novan has a 12 month low of $2.82 and a 12 month high of $7.85.
Separately, ValuEngine raised shares of Novan from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Novan (NOVN) Share Price” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/20/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-novan-novn-share-price.html.
Novan Company Profile
Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).
Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with MarketBeat.com's FREE daily email newsletter.